AKT1 E17K mutant phosphorylates RSK

Stable Identifier
R-HSA-2399999
Type
Reaction [transition]
Species
Homo sapiens
Compartment
nucleoplasm
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
AKT1 E17K mutant phosphorylates RSK
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
AKT1 E17K gain-of-function mutant is expected to phosphorylate ribosomal protein S6 kinase beta-2, like the wild-type AKT (Koh et al. 1999), but this has not been experimentally tested.
Literature References
PubMed ID Title Journal Year
10490848 Cloning and characterization of a nuclear S6 kinase, S6 kinase-related kinase (SRK); a novel nuclear target of Akt

Koh, H, Jee, K, Lee, B, Kim, J, Kim, D, Yun, YH, Kim, JW, Choi, HS, Chung, J

Oncogene 1999
Participants
Input
Output
Participates
as an event of
Catalyst Activity

protein serine/threonine kinase activity of p-T308,S473-AKT1 E17K [nucleoplasm]

Physical Entity
p-T308,S473-AKT1 E17K [nucleoplasm] (Homo sapiens)
Activity
protein serine/threonine kinase activity (GO:0004674)
Normal reaction
AKT can phosphorylate RSK (Homo sapiens)
Functional status

Gain of function of p-T308,S473-AKT1 E17K [nucleoplasm]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Orlic-Milacic, M  (2012-07-18)
Reviewed
Thorpe, L  (2012-08-13)
Yuzugullu, H  (2012-08-13)
Zhao, JJ  (2012-08-13)
Created
Orlic-Milacic, M  (2012-07-13)
Cite Us!